Showing posts with label Birth control. Show all posts
Showing posts with label Birth control. Show all posts

Thursday, November 3, 2011

Link Between Hormone In Birth Control Shot And Memory Loss


The birth control shot Depo Provera offers a convenient alternative for women who don't want to remember to take a daily pill. Ironically, research from Arizona State University has shown the shot actually may impair a person's memory.

The ASU study connects medroxyprogesterone acetate (MPA), the hormone active in Depo Provera and many widely used menopausal hormone therapies, to impaired memory in rodents. The study is currently in press in the journal Psychopharmacology. An early on line version of the article is available here.

The study was led by Blair Braden, an ASU psychology doctoral student, and Heather Bimonte-Nelson, an ASU associate professor of psychology and director of the Bimonte-Nelson Memory and Aging Lab. The work was done in collaboration with Laszlo Prokai from the University of North Texas Health Sciences Center, Fort Worth, Tex., and Alain Simard from Barrow Neurological Institute, Phoenix.

The Bimonte-Nelson lab first linked MPA to memory loss in rats while studying it as a component of hormone therapy for menopause. This earlier study showed that MPA impaired memory in menopausal-aged rats, and results were published in the November 2010 issue of Neurobiology of Learning and Memory. The current study specifically looks at the drug in relation to the birth control shot.

Bimonte-Nelson said she and Braden began asking questions about the effects of the drug because Braden was concerned about friends taking MPA as a contraceptive.
"This is an important question, because what we are going to have in our future are women who are menopausal that also have a history of taking MPA as birth control when they were younger," said Bimonte-Nelson.

The U.S. Food and Drug Administration originally approved Depo Provera for use in October 1992. It requires an injection every 12 weeks. Its 99 percent effectiveness and the infrequency of doses make the shot an attractive alternative for women seeking to avoid pregnancy.

While other studies have examined Depo Provera's effects on bone density, Bimonte-Nelson's lab is the first to explore its effects on cognition. The researchers note that other forms of hormonal contraception, such as the pill, do not use MPA.

The study lasted approximately one year, using three groups of rats (which received doses at varying ages), plus a control group that did not receive the hormone. To test their memory, rats were placed in water-based mazes to swim and seek out hidden platforms in the water.

"What we found was pretty shocking - animals that had been given the drug at any point in their life were memory impaired at middle age compared to animals that never had the drug," said Braden. "We also confirmed that in the subjects that only received the drug when young, the hormone was no longer circulating during memory testing when older, showing it had cleared from the system yet still had effects on brain function."

The researchers also measured a marker of the gamma-aminobutyric acid (GABA) neurotransmitter system in the hippocampus of the rats' brains to determine MPA's physiological effects.

"What GABA does is slow the brain down," Braden said. "So if there is too much of it, it can make it more difficult to produce memories. But then if there's too little of it and there's too much excitation, same thing - it makes you not able to produce memories correctly."

The group plans to follow the animal studies with human trials, and the work is leading to results that could have profound implications for women of all ages.

"This research shows that even after this hormone is no longer on board, months and months later, resulting effects are impacting the brain and its function," Bimonte-Nelson said. "This work is an important step forward in our understanding of the potentially long-lasting effects of clinically used hormones on brain function. However, more research is needed to determine whether these effects also occur in women that take this hormone as birth control or part of hormone therapy."

Friday, October 28, 2011

Contraceptive Birth Control Pills Double Risk Of Blood Clot

One of the largest studies to look at the link better "the pill" and blood clots, showed the older formulas to have a lower risk, but the newer versions to perform better in regards to venous thromboembolism (VTE). The researchers stressed that women should consult their doctor before changing brands or formulas.

Blood clots can be particularly dangerous because once formed in a peripheral vein, usually in the leg, the clot can break free and travel to more sensitive parts of the body, such as brain or vital organs.

Medical records of close to 1.3 million women were included in the study, with 30% of them never having used hormonal contraception, while nearly 70% had used some form of hormonal birth control.

Of the total, 4,307 cases of blood clots required treatment with (64%) as deep vein thrombosis (DVT), where a blood clot chokes circulation in a limb, causing a leg or arm to become swollen, stiff, or painful. 25% were blood clots in the lungs. Around 2% had blood clots that caused strokes.

The older-generation pill that contains an estrogen and the progestin hormone levonorgestrel roughly doubled the risk compared to women not on any hormonal birth control.

The newer kinds of pills, which contain the progestin hormones drospirenone, desogestrel, or gestodene along with estrogen, doubled the risk again, making it six to seven times as high as women who weren't using hormonal forms of birth control. On average, roughly 10 out of 10,000 women taking newer kinds of birth control pills had venous thromboembolism within a year.

The study which is probably going to trouble doctors, patients and drug companies alike, was published in BMJ, just as the FDA is reviewing the safety of newer birth control pills. The FDA birth control investigation was announced in May 2011 and is scheduled to be finished shortly.
In September, the agency said it had not yet reached a conclusion but :
"remains concerned about the potential increased risk of blood clots with the use of drospirenone-containing birth control pills."

The problem is that the wide use of the birth control pill can create a real public health problem even if its only small number statistically. Researcher Ojvind Lidegaard, MD, professor of obstetrics and gynecology, Rigshospitalet at the University of Copenhagen, in Denmark said : "
"You have to consider that 200 million women, every day, worldwide take such a pill. So even if it's only one in 500 per year who get the thrombosis if they are on a fourth-generation pill and are 30 years old, then you actually get a relatively high number of complications .... and you could actually halve that number just by changing the pill from a fourth- to a second-generation pill."

But experts say changing back to an older version of the pill may not be the smartest choice for all women. Philip C. Hannaford, MD, who is the Grampian Health Board chair of primary care at the University of Aberdeen, in Scotland, says in an email to WebMD.
"It is important to have a range of different oral contraceptives available because some women tolerate one preparation better than another."

Obviously some women prefer one kind of pill over another for practical daily reasons such as less nausea, fluid retention, acne, or weight gain.
"This means that clinicians and women often chose to use combined oral contraceptives which do not contain levonorgestrel, and this seems a pragmatic and sensible thing to do given that the background risk of DVT is very low."

It would also be important for women and their health care professionals to take into account other factors, such as medical history, family history and other risk factors such as smoking, alcohol consumption, weight and general health.
Written by Rupert Shepherd

Tuesday, October 4, 2011

Hormonal Contraceptives Double HIV Risk







Women using hormonal contraception - such as a birth control pill or a shot like Depo-Provera - are at double the risk of acquiring HIV, and HIV-infected women who use hormonal contraception have twice the risk of transmitting the virus to their HIV-uninfected male partners, according to a University of Washington-led study in Africa of nearly 3,800 couples. The study was published in The Lancet Infectious Diseases.

The research, first presented in July in Rome at the meeting of the International AIDS Society, emphasizes the need for couples to use condoms in addition to other forms of contraception in order to prevent pregnancy and HIV, said lead study author Renee Heffron, an epidemiology doctoral student working with the International Clinical Research Center at UW.

"Women should be counseled about potentially increased risk of HIV acquisition and transmission with hormonal contraception, particularly injectable methods, and about the importance of dual protection with condoms to decrease HIV risk," said Heffron.

Jared Baeten, an associate professor of global health with the International Clinical Research Center, said to his knowledge this is the first prospective study to show increased HIV risk to male partners of HIV-infected women using hormonal contraception.
More than 140 million women worldwide use hormonal contraception, including daily oral pills and long-acting injectables, like Depo-Provera.

"The benefits of effective hormonal contraception are unequivocal and must be balanced with the risk for HIV infection," said Baeten.

This study was designed to establish whether hormonal contraception increases the risk of women acquiring HIV and transmitting the virus to their male partners. The study included 3,790 heterosexual HIV serodiscordant couples (i.e. one partner with HIV infection and the other without) who were participating in two long-term studies of HIV in couples in seven African countries (Botswana, Kenya, Rwanda, South Africa, Tanzania, Uganda, and Zimbabwe).

Findings showed that using hormonal contraceptives doubled an HIV uninfected woman's chances of becoming infected with HIV. The risk was increased for both injectable (mainly depot medroxprogeterone acetate: DMPA) and oral contraceptives, although it was not statistically significant for oral contraceptives.

Additionally, women who were HIV-positive at the beginning of the study and using hormonal contraception were twice as likely to transmit the virus to their male partner compared to women who did not use hormonal contraception.
 
Design by Free WordPress Themes | Bloggerized by Lasantha -